Autologous Antibody Responses to an HIV Envelope Glycan Hole Are Not Easily Broadened in Rabbits.


Journal

Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724

Informations de publication

Date de publication:
17 03 2020
Historique:
received: 30 10 2019
accepted: 09 01 2020
pubmed: 17 1 2020
medline: 15 9 2020
entrez: 17 1 2020
Statut: epublish

Résumé

Extensive studies with subtype A BG505-derived HIV envelope glycoprotein (Env) immunogens have revealed that the dominant autologous neutralizing epitope in rabbits is located in an exposed region of the heavily glycosylated trimer that lacks potential N-linked glycosylation sites at positions 230, 241, and 289. The Env derived from B41, a subtype B virus, shares a glycan hole centered on positions 230 and 289. To test whether broader neutralization to the common glycan hole can be achieved, we immunized rabbits with B41 SOSIP (gp120-gp41 disulfide [SOS] with an isoleucine-to-proline mutation [IP] in gp41) alone, as well as B41 and BG505 coimmunization. We isolated autologous neutralizing antibodies (nAbs) and described their structure in complex with the B41 Env. Our data suggest that distinct autologous nAb lineages are induced by BG505 and B41 immunogens, even when both were administered together. In contrast to previously described BG505 glycan hole antibodies, the B41-specific nAbs accommodate the >97% conserved N241 glycan, which is present in B41. Single-particle cryo-electron microscopy studies confirmed that B41- and BG505-specific nAbs bind to overlapping glycan hole epitopes. We then used our high-resolution data to guide mutations in the BG505 glycan hole epitope in an attempt to broaden the reactivity of a B41-specific nAb, but we recovered only partial binding. Our data demonstrate that the lack of cross-reactivity in glycan hole antibodies is due to amino acid differences within the epitope, and our attempts to rationally design cross-reactive trimers resulted in only limited success. Thus, even for the immunodominant glycan hole shared between BG505 and B41, the prospect of designing prime-boost immunogens remains difficult.

Identifiants

pubmed: 31941772
pii: JVI.01861-19
doi: 10.1128/JVI.01861-19
pmc: PMC7081899
pii:
doi:

Substances chimiques

Antibodies, Neutralizing 0
HIV Antibodies 0
Immunodominant Epitopes 0
Polysaccharides 0
env Gene Products, Human Immunodeficiency Virus 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : F31 AI131873
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI110657
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI100663
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI144462
Pays : United States

Informations de copyright

Copyright © 2020 Yang et al.

Références

Nucleic Acids Res. 2014 Jan;42(Database issue):D1133-9
pubmed: 24214957
J Virol. 2002 Sep;76(17):8875-89
pubmed: 12163607
Nat Methods. 2015 Oct;12(10):943-6
pubmed: 26280328
Annu Rev Immunol. 2016 May 20;34:635-59
pubmed: 27168247
J Virol. 2006 Mar;80(5):2515-28
pubmed: 16474158
J Virol. 2002 Aug;76(15):7760-76
pubmed: 12097589
J Virol. 2018 Mar 28;92(8):
pubmed: 29367243
J Virol. 2005 Aug;79(16):10108-25
pubmed: 16051804
J Virol. 2015 Mar;89(6):3380-95
pubmed: 25589637
Cell Rep. 2016 Aug 30;16(9):2327-38
pubmed: 27545891
Cell Rep. 2019 Apr 9;27(2):586-598.e6
pubmed: 30970260
J Struct Biol. 2009 Apr;166(1):95-102
pubmed: 19263523
Cell Rep. 2018 Oct 23;25(4):893-908.e7
pubmed: 30355496
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Bioinformatics. 2014 Nov 15;30(22):3276-8
pubmed: 25095880
J Struct Biol. 2016 Jan;193(1):1-12
pubmed: 26592709
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
Immunity. 2014 May 15;40(5):669-80
pubmed: 24768348
Elife. 2016 Sep 26;5:
pubmed: 27669148
Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):E7039-E7048
pubmed: 27791170
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
Immunity. 2014 May 15;40(5):657-68
pubmed: 24768347
Nat Rev Immunol. 2019 Feb;19(2):77-78
pubmed: 30560910
PLoS One. 2013 May 22;8(5):e63906
pubmed: 23717507
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17624-9
pubmed: 25422458
PLoS Pathog. 2018 Feb 23;14(2):e1006913
pubmed: 29474444
J Virol. 2003 Jan;77(1):353-65
pubmed: 12477840
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Nat Immunol. 2015 Jun;16(6):571-6
pubmed: 25988889
J Struct Biol. 2000 Oct;132(1):33-45
pubmed: 11121305
PLoS Pathog. 2016 Sep 14;12(9):e1005864
pubmed: 27627672
Nat Methods. 2017 Apr;14(4):331-332
pubmed: 28250466
Immunity. 2018 Aug 21;49(2):288-300.e8
pubmed: 30097292
Cell Rep. 2020 Mar 17;30(11):3755-3765.e7
pubmed: 32187547

Auteurs

Yuhe R Yang (YR)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, USA.
IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, USA.

Laura E McCoy (LE)

Division of Infection and Immunity, University College London, London, United Kingdom.

Marit J van Gils (MJ)

Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Raiees Andrabi (R)

Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, USA.
IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.

Hannah L Turner (HL)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, USA.
IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, USA.

Meng Yuan (M)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, USA.
IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, USA.

Christopher A Cottrell (CA)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, USA.
IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, USA.

Gabriel Ozorowski (G)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, USA.
IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, USA.

James Voss (J)

Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, USA.
IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.

Matthias Pauthner (M)

Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, USA.
IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.

Thomas M Polveroni (TM)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, USA.
IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, USA.

Terrence Messmer (T)

Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, USA.
IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.

Ian A Wilson (IA)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA.
Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, USA.
IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, USA.
Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California, USA.

Rogier W Sanders (RW)

Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York, USA.

Dennis R Burton (DR)

Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, USA burton@scripps.edu andrew@scripps.edu.
IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, USA.
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, USA.

Andrew B Ward (AB)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California, USA burton@scripps.edu andrew@scripps.edu.
Scripps Consortium for HIV/AIDS Vaccine Development (CHAVD), The Scripps Research Institute, La Jolla, California, USA.
IAVI Neutralizing Antibody Center and the Collaboration for AIDS Vaccine Discovery (CAVD), The Scripps Research Institute, La Jolla, California, USA.
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH